Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)

In the Russian Federation, liver diseases are most frequently represented by two their nosological forms, i.e., nonalcoholic and alcoholic fatty liver disease (NAFLD and ALD). A successful management of such patients, along with improving the functional state of the liver, requires a careful analysi...

Full description

Saved in:
Bibliographic Details
Main Authors: M. V. Mayevskaya, V. T. Ivashkin, V. D. Lunkov, S. P. Kryzhanovskiy, I. Yu. Pirogova, Ch. S. Pavlov, M. S. Zharkova, A. G. Beniashvili, M. A. Morozova
Format: Article
Language:Russian
Published: Gastro LLC 2018-11-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/264
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860127853182976
author M. V. Mayevskaya
V. T. Ivashkin
V. D. Lunkov
S. P. Kryzhanovskiy
I. Yu. Pirogova
Ch. S. Pavlov
M. S. Zharkova
A. G. Beniashvili
M. A. Morozova
author_facet M. V. Mayevskaya
V. T. Ivashkin
V. D. Lunkov
S. P. Kryzhanovskiy
I. Yu. Pirogova
Ch. S. Pavlov
M. S. Zharkova
A. G. Beniashvili
M. A. Morozova
author_sort M. V. Mayevskaya
collection DOAJ
description In the Russian Federation, liver diseases are most frequently represented by two their nosological forms, i.e., nonalcoholic and alcoholic fatty liver disease (NAFLD and ALD). A successful management of such patients, along with improving the functional state of the liver, requires a careful analysis of patients’ nonspecific complaints. In particular, it is important to investigate asthenic syndrome, which can indirectly result in the exacerbation of liver diseases, thus incurring additional economic costs to national healthcare systems. Therefore, the elucidation of the nature of asthenic syndrome and a search for methods for its resolution seem to be highly relevant research tasks.Aim. This study aims to investigate the effect of the antioxidant drug (the extract of the Amur maackia wood) on the organic and functional components of asthenic syndrome in patients with NAFLD and ALD, who do not show signs of the disease decompensation. Materials and methods. An observational program was carried out under the conditions of daily clinical practice in three Russian cities: Moscow, Chelyabinsk and Vladivostok. 80 patients (40 with NAFLD, 40 with ALD) were comprehensively examined according to a developed program. A number of laboratory indicators that reveal inflammatory processes in the liver were studied, including leukocytes, ESR, ALT, AST, GGTP and CRP. The patients’ psycho-emotional status was assessed using a Daily Fatigue Impact Scale (D-FIS) and a four-dimensional scale for assessing distress, depression, anxiety and somatisation (4DSQ). Results. According to the D-FIS questionnaire, all the patients showed fatigue. According to the 4DSQ questionnaire, a correlation of distress with the level of laboratory indicators was revealed among all the patients. No such a correlation was noted for depression and anxiety in the patients with NAFLD. On the contrary, in the case of ALD, all psycho-emotional disorders (except for somatisation) were positively correlated with the markers of inflammation. It is shown that asthenic syndrome in patients with both NAFLD and ALD has a complex origin, being associated both with inflammatory processes in the liver and psycho-emotional disorders. In all cases under study, the prescription of the preparation led to a decrease in the studied laboratory indicators (inflammation markers) and an increase in the patients’ psycho-emotional status. The latter improvement was manifested in the reduction of distress, depression, anxiety and somatisation, according to the 4DSQ questionnaire, as well as in the reduction of fatigue, according to the D-FIS questionnaire.Conclusion. The results of the observational program have shown that patients with NAFLD and ALD frequently experience such components of asthenic syndrome as distress, depression, anxiety, somatisation and fatigue. The prescription of the preparation is found to result in a decrease in laboratory inflammatory indicators. In addition, the preparation is determined to positively affect the components of asthenic syndrome in patients with NAFLD and ALD. In the course of the treatment, no clinically significant side effects were documented.
format Article
id doaj-art-54035edccef64a94b620d1f13c596d77
institution Kabale University
issn 1382-4376
2658-6673
language Russian
publishDate 2018-11-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj-art-54035edccef64a94b620d1f13c596d772025-02-10T16:14:35ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732018-11-01285779710.22416/1382-4376-2018-28-5-77-97263Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)M. V. Mayevskaya0V. T. Ivashkin1V. D. Lunkov2S. P. Kryzhanovskiy3I. Yu. Pirogova4Ch. S. Pavlov5M. S. Zharkova6A. G. Beniashvili7M. A. Morozova8I.M. Sechenov First Moscow State Medical University (Sechenov University).I.M. Sechenov First Moscow State Medical University (Sechenov University).I.M. Sechenov First Moscow State Medical University (Sechenov University).Medical Association of the Far Eastern Branch of the Russian Academy of Sciences.Gastroenterology and Hepatology Medical Centre Lotos.I.M. Sechenov First Moscow State Medical University (Sechenov University).I.M. Sechenov First Moscow State Medical University (Sechenov University).Mental Health Research Center.Mental Health Research Center.In the Russian Federation, liver diseases are most frequently represented by two their nosological forms, i.e., nonalcoholic and alcoholic fatty liver disease (NAFLD and ALD). A successful management of such patients, along with improving the functional state of the liver, requires a careful analysis of patients’ nonspecific complaints. In particular, it is important to investigate asthenic syndrome, which can indirectly result in the exacerbation of liver diseases, thus incurring additional economic costs to national healthcare systems. Therefore, the elucidation of the nature of asthenic syndrome and a search for methods for its resolution seem to be highly relevant research tasks.Aim. This study aims to investigate the effect of the antioxidant drug (the extract of the Amur maackia wood) on the organic and functional components of asthenic syndrome in patients with NAFLD and ALD, who do not show signs of the disease decompensation. Materials and methods. An observational program was carried out under the conditions of daily clinical practice in three Russian cities: Moscow, Chelyabinsk and Vladivostok. 80 patients (40 with NAFLD, 40 with ALD) were comprehensively examined according to a developed program. A number of laboratory indicators that reveal inflammatory processes in the liver were studied, including leukocytes, ESR, ALT, AST, GGTP and CRP. The patients’ psycho-emotional status was assessed using a Daily Fatigue Impact Scale (D-FIS) and a four-dimensional scale for assessing distress, depression, anxiety and somatisation (4DSQ). Results. According to the D-FIS questionnaire, all the patients showed fatigue. According to the 4DSQ questionnaire, a correlation of distress with the level of laboratory indicators was revealed among all the patients. No such a correlation was noted for depression and anxiety in the patients with NAFLD. On the contrary, in the case of ALD, all psycho-emotional disorders (except for somatisation) were positively correlated with the markers of inflammation. It is shown that asthenic syndrome in patients with both NAFLD and ALD has a complex origin, being associated both with inflammatory processes in the liver and psycho-emotional disorders. In all cases under study, the prescription of the preparation led to a decrease in the studied laboratory indicators (inflammation markers) and an increase in the patients’ psycho-emotional status. The latter improvement was manifested in the reduction of distress, depression, anxiety and somatisation, according to the 4DSQ questionnaire, as well as in the reduction of fatigue, according to the D-FIS questionnaire.Conclusion. The results of the observational program have shown that patients with NAFLD and ALD frequently experience such components of asthenic syndrome as distress, depression, anxiety, somatisation and fatigue. The prescription of the preparation is found to result in a decrease in laboratory inflammatory indicators. In addition, the preparation is determined to positively affect the components of asthenic syndrome in patients with NAFLD and ALD. In the course of the treatment, no clinically significant side effects were documented.https://www.gastro-j.ru/jour/article/view/264non-alcoholic fatty liver diseasealcoholic liver diseaseinflammationasthenic syndromedistressdepressionanxietysomatisation
spellingShingle M. V. Mayevskaya
V. T. Ivashkin
V. D. Lunkov
S. P. Kryzhanovskiy
I. Yu. Pirogova
Ch. S. Pavlov
M. S. Zharkova
A. G. Beniashvili
M. A. Morozova
Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
non-alcoholic fatty liver disease
alcoholic liver disease
inflammation
asthenic syndrome
distress
depression
anxiety
somatisation
title Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
title_full Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
title_fullStr Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
title_full_unstemmed Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
title_short Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
title_sort antioxidants in the treatment of chronic diffuse liver diseases the results of the maxar observational program
topic non-alcoholic fatty liver disease
alcoholic liver disease
inflammation
asthenic syndrome
distress
depression
anxiety
somatisation
url https://www.gastro-j.ru/jour/article/view/264
work_keys_str_mv AT mvmayevskaya antioxidantsinthetreatmentofchronicdiffuseliverdiseasestheresultsofthemaxarobservationalprogram
AT vtivashkin antioxidantsinthetreatmentofchronicdiffuseliverdiseasestheresultsofthemaxarobservationalprogram
AT vdlunkov antioxidantsinthetreatmentofchronicdiffuseliverdiseasestheresultsofthemaxarobservationalprogram
AT spkryzhanovskiy antioxidantsinthetreatmentofchronicdiffuseliverdiseasestheresultsofthemaxarobservationalprogram
AT iyupirogova antioxidantsinthetreatmentofchronicdiffuseliverdiseasestheresultsofthemaxarobservationalprogram
AT chspavlov antioxidantsinthetreatmentofchronicdiffuseliverdiseasestheresultsofthemaxarobservationalprogram
AT mszharkova antioxidantsinthetreatmentofchronicdiffuseliverdiseasestheresultsofthemaxarobservationalprogram
AT agbeniashvili antioxidantsinthetreatmentofchronicdiffuseliverdiseasestheresultsofthemaxarobservationalprogram
AT mamorozova antioxidantsinthetreatmentofchronicdiffuseliverdiseasestheresultsofthemaxarobservationalprogram